Skip to main content
Erschienen in: International Journal of Hematology 5/2017

04.07.2017 | Original Article

Plasma chitotriosidase and carotid intima–media thickness in children with sickle cell disease

verfasst von: Normeen A. Kaddah, Dalia A. Saied, Hanan A. Alwakeel, Rania H. Hashem, Sara M. Rowizak, Mohamed A. Elmonem

Erschienen in: International Journal of Hematology | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

The relationship between chronic hemolysis with subsequent iron overload, inflammation, and premature atherosclerosis has been documented in hemolytic anemias, particularly β-thalassemia. However, no such relationship has been established in sickle cell disease (SCD). We sought to evaluate SCD as a risk factor for early vascular insult by measuring carotid intima–media thickness (CIMT) and plasma chitotriosidase and to assess the role of the latter as a potential quantitative indicator of vascular inflammation and atherogenesis. Thirty SCD pediatric patients (3–18 years) and 30 matched controls were enrolled. Full clinical history, with hematological and biochemical parameters, was evaluated. CIMT and chitotriosidase activity were also assessed for all study participants. CIMT values were significantly higher in SCD patients (median 0.42; range 0.32–0.6 mm) compared to controls (0.36; 0.34–0.45 mm), P = 0.03. CIMT correlated positively with age (r = 0.460, P = 0.011), and total number of vascular incidents necessitating hospital admission (r = 0.439, P = 0.015). Similarly, chitotriosidase activity was significantly higher among SCD patients (median 59.6; range 7.3–512 nmol/ml plasma/h) compared to controls (32.7; 6.8–63.1 nmol/ml plasma/h), P < 0.001, and showed a positive correlation with serum ferritin (r = 0.517, P = 0.003) and CIMT (r = 0.535, P = 0.002). SCD children are at risk of developing premature atherogenic changes. Plasma chitotriosidase and CIMT may represent useful predictors of these changes.
Literatur
1.
Zurück zum Zitat Ingram VM. Gene mutations in human haemoglobin: the chemical difference between normal and sickle cell haemoglobin. Nature. 1957;180:326–8.CrossRefPubMed Ingram VM. Gene mutations in human haemoglobin: the chemical difference between normal and sickle cell haemoglobin. Nature. 1957;180:326–8.CrossRefPubMed
3.
Zurück zum Zitat Lal A, Vichinsky EP. Sickle cell anemia. In: Hoffbrand AV, Catovesky D, Tuddenham EGD, editors. Postgraduate haematology. 5th ed. New York: Wiley; 2005. p. 105–18. Lal A, Vichinsky EP. Sickle cell anemia. In: Hoffbrand AV, Catovesky D, Tuddenham EGD, editors. Postgraduate haematology. 5th ed. New York: Wiley; 2005. p. 105–18.
6.
7.
Zurück zum Zitat Finn AV, Kolodgie FD, Virmani R. Correlation between carotid intimal/medial thickness and atherosclerosis: a point of view from pathology. Arterioscler Thromb Vasc Biol. 2010;30:177–81.CrossRefPubMed Finn AV, Kolodgie FD, Virmani R. Correlation between carotid intimal/medial thickness and atherosclerosis: a point of view from pathology. Arterioscler Thromb Vasc Biol. 2010;30:177–81.CrossRefPubMed
8.
Zurück zum Zitat Setty BN, Kulkarni S, Rao AK, Stuart MJ. Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation. Blood. 2000;96:1119–24.PubMed Setty BN, Kulkarni S, Rao AK, Stuart MJ. Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidylserine exposure and coagulation activation. Blood. 2000;96:1119–24.PubMed
9.
Zurück zum Zitat Hahalis G, Kremastinos DT, Terzis G, Kalogeropoulos AP, Chrysanthopoulou A, Karakantza M, et al. Global vasomotor dysfunction and accelerated vascular aging in beta-thalassemia major. Atherosclerosis. 2008;198:448–57.CrossRefPubMed Hahalis G, Kremastinos DT, Terzis G, Kalogeropoulos AP, Chrysanthopoulou A, Karakantza M, et al. Global vasomotor dysfunction and accelerated vascular aging in beta-thalassemia major. Atherosclerosis. 2008;198:448–57.CrossRefPubMed
10.
Zurück zum Zitat Arbones-Mainar JM, Navarro MA, Guzman MA, Arnal C, Surra JC, Acin S, et al. Selective effect of conjugated linoleic acid isomers on atherosclerotic lesion development in apolipoprotein E knockout mice. Atherosclerosis. 2006;189:318–27.CrossRefPubMed Arbones-Mainar JM, Navarro MA, Guzman MA, Arnal C, Surra JC, Acin S, et al. Selective effect of conjugated linoleic acid isomers on atherosclerotic lesion development in apolipoprotein E knockout mice. Atherosclerosis. 2006;189:318–27.CrossRefPubMed
11.
Zurück zum Zitat Artieda M, Cenarro A, Gañán A, Lukie A, Moreno E, Puzo J, et al. Serum Chitotriosidase activity. A marker of activated macrophages, predicts new cardiovascular events independently of C-reactive protein. Cardiology. 2007;108:297–306.CrossRefPubMed Artieda M, Cenarro A, Gañán A, Lukie A, Moreno E, Puzo J, et al. Serum Chitotriosidase activity. A marker of activated macrophages, predicts new cardiovascular events independently of C-reactive protein. Cardiology. 2007;108:297–306.CrossRefPubMed
12.
Zurück zum Zitat Barone R, Di Gregorio F, Romeo MA, Schilirò G, Pavone L. Plasma chitotriosidase activity in patients with beta-thalassemia. Blood Cells Mol Dis. 1999;24:1–8.CrossRef Barone R, Di Gregorio F, Romeo MA, Schilirò G, Pavone L. Plasma chitotriosidase activity in patients with beta-thalassemia. Blood Cells Mol Dis. 1999;24:1–8.CrossRef
13.
Zurück zum Zitat Tantawy AG, Adly AM, El Maaty GA, Amin AG. Subclinical atherosclerosis in young β-thalassemia major patients. Hemoglobin. 2009;33:463–74.CrossRefPubMed Tantawy AG, Adly AM, El Maaty GA, Amin AG. Subclinical atherosclerosis in young β-thalassemia major patients. Hemoglobin. 2009;33:463–74.CrossRefPubMed
14.
Zurück zum Zitat Gursel O, Kurekci AE, Tascilar E, Ileri T, Altun D, Tapan S, et al. Premature atherosclerosis in children with β-thalassemia major. J Pediatr Hematol Oncol. 2012;34:630–4.CrossRefPubMed Gursel O, Kurekci AE, Tascilar E, Ileri T, Altun D, Tapan S, et al. Premature atherosclerosis in children with β-thalassemia major. J Pediatr Hematol Oncol. 2012;34:630–4.CrossRefPubMed
15.
Zurück zum Zitat Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO 3rd, Schechter AN, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8:1383–9.CrossRefPubMed Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO 3rd, Schechter AN, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med. 2002;8:1383–9.CrossRefPubMed
16.
Zurück zum Zitat Cheung YF, Chow PC, Chan GC, Ha Y. Carotid intima-media thickness is increased and related to arterial stiffening in patients with β-thalassemia major. Br J Haematol. 2006;135:732–4.CrossRefPubMed Cheung YF, Chow PC, Chan GC, Ha Y. Carotid intima-media thickness is increased and related to arterial stiffening in patients with β-thalassemia major. Br J Haematol. 2006;135:732–4.CrossRefPubMed
17.
Zurück zum Zitat Elmonem MA, Ramadan DI, Issac MS, Selim LA, Elkateb SM. Blood spot versus plasma chitotriosidase: a systematic clinical comparison. Clin Biochem. 2014;47:38–43.CrossRefPubMed Elmonem MA, Ramadan DI, Issac MS, Selim LA, Elkateb SM. Blood spot versus plasma chitotriosidase: a systematic clinical comparison. Clin Biochem. 2014;47:38–43.CrossRefPubMed
18.
Zurück zum Zitat You SA, Archacki SR, Angheloiu G, Moravec CS, Rao S, Kinter M, et al. Proteomic approach to coronary atherosclerosis shows ferritin light chain as a significant marker: evidence consistent with iron hypothesis in atherosclerosis. Physiol Genom. 2003;13:25–30.CrossRef You SA, Archacki SR, Angheloiu G, Moravec CS, Rao S, Kinter M, et al. Proteomic approach to coronary atherosclerosis shows ferritin light chain as a significant marker: evidence consistent with iron hypothesis in atherosclerosis. Physiol Genom. 2003;13:25–30.CrossRef
19.
Zurück zum Zitat Renkema GH, Boot RG, Muijsers AO, Donker-Koopman WE, Aerts JMFG. Purification and characterization of human chitotriosidase, a novel member of the chitinase family of proteins. J Biol Chem. 1995;270:2198–209.CrossRefPubMed Renkema GH, Boot RG, Muijsers AO, Donker-Koopman WE, Aerts JMFG. Purification and characterization of human chitotriosidase, a novel member of the chitinase family of proteins. J Biol Chem. 1995;270:2198–209.CrossRefPubMed
20.
Zurück zum Zitat Boot RG, Van Achterberg TA, Van Aken BE, Renkema GH, Jacobs MJ, Aerts JM, et al. Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler Thromb Vasc Biol. 1999;19:687–94.CrossRefPubMed Boot RG, Van Achterberg TA, Van Aken BE, Renkema GH, Jacobs MJ, Aerts JM, et al. Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler Thromb Vasc Biol. 1999;19:687–94.CrossRefPubMed
21.
Zurück zum Zitat Sun Q, Ma J, Rifai N, Franco OH, Rexrode KM, Hu FB. Excessive body iron stores are not associated with risk of coronary heart disease in women. J Nutr. 2008;138:2436–41.CrossRefPubMedPubMedCentral Sun Q, Ma J, Rifai N, Franco OH, Rexrode KM, Hu FB. Excessive body iron stores are not associated with risk of coronary heart disease in women. J Nutr. 2008;138:2436–41.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Tantawy AA, Adly AA, Ismail EA, Abdelazeem M. Clinical predictive value of cystatin C in pediatric sickle cell disease: a marker of disease severity and subclinical cardiovascular dysfunction. Clin Appl Thromb Hemostat. 2016. [Epub ahead of print]. pii: 1076029616665921. Tantawy AA, Adly AA, Ismail EA, Abdelazeem M. Clinical predictive value of cystatin C in pediatric sickle cell disease: a marker of disease severity and subclinical cardiovascular dysfunction. Clin Appl Thromb Hemostat. 2016. [Epub ahead of print]. pii: 1076029616665921.
Metadaten
Titel
Plasma chitotriosidase and carotid intima–media thickness in children with sickle cell disease
verfasst von
Normeen A. Kaddah
Dalia A. Saied
Hanan A. Alwakeel
Rania H. Hashem
Sara M. Rowizak
Mohamed A. Elmonem
Publikationsdatum
04.07.2017
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 5/2017
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-017-2288-z

Weitere Artikel der Ausgabe 5/2017

International Journal of Hematology 5/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.